暴露于 Ibrexafunerp 的怀孕受试者的安全性,包括婴儿结果
对怀孕期间接触 Ibrexafungerp 的受试者进行的单臂安全性研究,包括长达一年的婴儿结果
This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.
研究概览
详细说明
This is a single-arm safety study which comprises an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age who were exposed to ibrexafungerp during pregnancy, or whose conception is estimated to have occurred within four days after receiving last dose of ibrexafungerp, and are volunteering to take part in this study. Subjects will be monitored starting from exposure during pregnancy until one year after live delivery.
Information on pregnancy outcomes and complications as well as fetal/neonatal/infant outcomes will be collected during the timeframe described in the protocol.
Subjects can enroll in the study by calling the telephone number directly (1-888-982-7299) or through SCYNEXIS BREXAFEMME Pregnancy Study Webpage, OR her healthcare provider (HCP) can, with her consent, enroll her on her behalf.
Data will be collected both retrospectively and prospectively using a variety of questionnaire that will be completed by the representative based on interview with the subject and/or HCP
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Sanjeev Miglani, MD
- 电话号码:+91-9910533655
- 邮箱:sanjeev.miglani@awinsals.com
学习地点
-
-
Vasant Vihar
-
New Delhi、Vasant Vihar、印度、110057
- 招聘中
- AWINSA
-
接触:
- Sanjeev Miglani, MD
- 电话号码:+91-9910533655
- 邮箱:sanjeev.miglani@awinsals.com
-
首席研究员:
- Sanjeev Miglani, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The study population will include women who were exposed to ibrexafungerp at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving last dose of ibrexafungerp, volunteering to take part in this study.
描述
Inclusion Criteria:
-
Exposure to ibrexafungerp during pregnancy or if conception is estimated to have occurred within 4 days of the last dose of ibrexafungerp
-
Subject and/or parent/legal representative consents to participate and agrees to the conditions and requirements of the study including the interview schedule/completion of questionnaire and release of medical records
- Subject can be identified by the sponsor or HCP, in terms of confirmed pregnancy.
A self-reported pregnancy will be considered as confirmed pregnancy if the Urine Pregnancy Test (UPT) result is positive.
- A woman can self-enroll in the study or her healthcare provider (HCP), with her consent, can enroll her on her behalf.
Exclusion Criteria:
- Females who were not exposed to safety study medications during pregnancy
- Refusal to participate in the study
- An inability to provide an accurate medical history or give informed consent
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:OTHER
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Study Cohort
Subjects who have been treated with Brexafemme (Ibrexafungerp) at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving the last dose of Brexafemme. |
This is not an interventional study |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major Structural Defects
大体时间:From Brexafemme exposure up to one year after birth
|
To collect and describe selected fetal/neonatal/infant outcomes (i.e., major and minor congenital malformations, small for gestational age, and postnatal growth and development) at birth and through up to the first year of life of infants born to women exposed to ibrexafungerp during the defined pregnancy exposure window |
From Brexafemme exposure up to one year after birth
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To collect and describe pregnancy outcomes
大体时间:From Brexafemme exposure up to one year post birth
|
Live birth, spontaneous abortions, stillbirths, elective abortions, and preterm births |
From Brexafemme exposure up to one year post birth
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 222030
- SCY-078-401 (其他标识符:Scynexis)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.